| | Publications: Books: Hall DP. Breaking Through Depression: Biblical and Medical
Approaches to Wholeness. Harvest House Publishers. Eugene, Oregon. 2009. Hall DP. Handbook of Psychiatric Drugs. Current Clinical Strategies Publishing.
Laguna Hills, CA. 1997. Hall DP. 200
Tips for Passing the Oral Psychiatry Boards.Hanley and Belphus, Inc. Philadelphia, PA. 1997.
Selected Journal Articles:
Waits W, Hall DP. Gabapentin in the treatment of bipolar disorder. Jefferson Journal of Psychiatry.
1998; 14:24-29.
Hall DP. Peacekeeping duty and PTSD (letter). American Journal of Psychiatry.
1997; 154:1482-1483.
Hall DP, Cipriano ED. Frustrated aggression and psychiatric casualties of Operation Uphold
Democracy.Journal of Nervous and Mental Disease. 1996; 184:377-378.
Hall DP. Stress,
suicide, and military service during Operation Uphold Democracy.Military Medicine. 1996; 161:159-162.
Hall DP, Benedek DM. Ultradian cycles of mood in normal and depressed subjects.Jefferson Journal of Psychiatry.
1996; 13:9-17.
Hall DP, Benedek DM. Adjustment disorder criteria (letter). Hospital and Community Psychiatry.
1993; 44:592.
Hall DP. A widow's grief: the language of the heart. Journal of the American Medical
Association. 1992; 268: 871-872.
Hall DP, Young SA. Frontal lobe cerebral aneurysm rupture presenting
as psychosis.Journal of Neurology, Neurosurgery, and Psychiatry. 1992; 55:1207-1208.
Hall
DP, Sing HC, Romanoski, AJ. The identification and characterization of greater mood variance in depression.American
Journal of Psychiatry. 1991; 148:1341-1345.
Hall DP. Exploring frontal lobe dysfunction in schizophrenia
with positron emission tomography.Jefferson Journal of Psychiatry. 1990; 8:50-58.
Ksir
C, Hakan R, Hall DP, Kellar KJ. Exposure to nicotine enhances the behavioral stimulant effect of nicotine and increases binding
of 3H-acetylcholine to nicotinic receptors.Neuropharmacology. 1985; 24:527-531.
Kellar
KJ, Schwartz RD, Martino AM, Hall DP. 3H- acetylcholine binding to muscarinic an nicotinic cholinergic receptors in brain:
utility for study of neuropsychiatric disease. Neuropharmacology. 1984; 7 (suppl.1):954-955.
|